Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human... see more

Recent & Breaking News (NYSE:MRK)

Merck to Participate at the Morgan Stanley Global Healthcare Conference

Business Wire September 9, 2016

FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Business Wire September 7, 2016

Merck Remains Stable Following Discontinuation Of Odanacatib Development Program

Benzinga.com  September 2, 2016

Merck Provides Update on Odanacatib Development Program

Business Wire September 2, 2016

The 2015 Flash Crash Was One Year Ago Today. Why Did It Happen?

Benzinga.com  August 24, 2016

Write A Prescription For More Pharma M&A With This ETF

Benzinga.com  August 24, 2016

InvestorsObserver releases covered-call reports for NVIDIA, Dicks Sporting Goods, Cintas, Priceline and Merck & Company Incorporated

PR Newswire August 17, 2016

Biogen Cancels Out Of Citigroup Conference Following Weeks Of Rumors

Benzinga.com  August 11, 2016

Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target

Benzinga.com  August 10, 2016

Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine

Business Wire August 8, 2016

The Market in 5 Minutes: Can The Momentum Continue?

Benzinga.com  August 8, 2016

REPEAT/FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

Business Wire August 8, 2016

Antibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in Osteoarthritis

Business Wire August 8, 2016

Watch These 5 Huge Put Purchases In Monday Trade

Benzinga.com  August 8, 2016

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

Business Wire August 5, 2016

25 Biggest Mid-Day Gainers For Friday

Benzinga.com  August 5, 2016

Benzinga's Volume Movers

Benzinga.com  August 5, 2016

Stocks Hitting 52-Week Highs

Benzinga.com  August 5, 2016

Bristol's Opdivo Misses Endpoint In Late-Stage Trial; Merck Rallies Sharply Amid Keytruda Potential

Benzinga.com  August 5, 2016

Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine

Business Wire August 5, 2016
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested